Search results

32 results

Sorted by Relevance . Sort by Date

  1. Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage (IPG701)

    Evidence-based recommendations on inducing and maintaining normothermia using temperature modulation devices after stroke or subarachnoid haemorrhage in adults

  2. Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids (IPG704)

    Evidence-based recommendations on hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids in adults. This involves cutting the

  3. Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (IPG706)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis in

  4. Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair (IPG707)

    Evidence-based recommendations transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This

  5. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation

  6. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)

    Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMA

  7. Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

    Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults

  8. Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

    Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome

  9. Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)

    Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or

  10. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults

  11. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation

  12. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation

  13. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation

  14. Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced non-squamous non-small-cell lung cancer in adults after chemotherapy

  15. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer

  16. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)

    Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine t